Prevention and Reversal by Enalapril of Target Organ Damage in Angiotensin II Hypertension

Abstract

Angiotensin-converting enzyme inhibitors (ACE-Is) prevent target organ damage in several models of hypertension. The aim of this study was to assess the influence of the ACE-I enalapril (10 mg/kg^-1 per day, gavage) on the cardiovascular alterations and production of free radicals induced by chronic infusion of angiotensin II (Ang II, 200 ng/kg^-1 per minute, SC) in Sprague-Dawley rats. Enalapril was given concomitantly for the 10 days of Ang II infusion (prevention) or from day 10 to 17 of Ang II infusion (intervention). The influence of the NADPH oxidase inhibitor apocynin (600 mg/L^-1 in drinking water) was evaluated. mg/L-^l in drinking water) was evaluated. Enalapril and apocynin had no effect on hypertension in the prevention and intervention studies. Enalapril prevented the increase in heart weight index (HWI), carotid cross-sectional area (CSA) and albuminuria induced by Ang II. Enalapril reduced HWI and albuminuria whereas CSA I was not affected in the intervention study. Apocynin had effects comparable to enalapril. Both enalapril and apocynin reduced the overproduction of superoxide anion by the left ventricle and rise in advanced oxidation protein products induced by C Ang II. Therefore, the antioxidant but not the antihypertensive effect of enalapril may participate in the prevention and treatment of the Ang II-induced cardiovascular and renal alterations.

Keywords

ACE inhibitors (ACE-Is)Cardiac hypertrophy Proteinuria Oxidative stress NADPH oxidase

Get full access to this article

View all access options for this article.

References

Lee Rmkw , Berecek KH , Tsoporis J. , McKenzie R. , Triggle CR Prevention of hypertension and vascular changes by captopril treatment. Hypertension 1991;17:141-50.

Linz W.H. , Schaper J. , Wiemer G. , Albus U. , Schölkens BA Ramip Oril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol 1992;107:970-5.

Herizi A. , Demeillers B. , Jover B. , Mimran A. Cardioprotective effect of enalapril in renovascular and angiotensin II hypertension . Clin Exp Hypertens 1997;19:953-64.

Anderson S. , Rennke HG , Brenner BM Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int 1992;41:891-7.

Lewis EJ , Hunsicker LG , Bain RP , Rohde RD : The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.

Sadoshima JI , Izumo S. Molecular characterization of angiotensin-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of AT1 receptor subtype. Circ Res 1993 ;73:413-23.

Laursen JB , Rajagopalan S. , Galis Z. , Tarpey M. , Freeman BA , Harrison DG Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1995;95:588-93.

Griendling KK , Minieri CA , Ollerenshaw JD , Alexander RW Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-8.

Wolf G. Free radical production and angiotensin. Curr Hypertens Rep 2000;66:167-73.

10.

Delbosc S. , Cristol JP , Descomps B. , Mimran A. , Jover B. Simvastatin prevents angiotensin II-induced cardiac alterations and oxidative stress. Hypertension 2002;40:142-7.

11.

Rugale C. , Delbosc S. , Cristol JP , Mimran A. , Jover B. Sodium restriction prevents cardiac hypertrophy and oxidative stress in angiotensin II hypertension. Am J Physiol Heart Circ Physiol 2003;284:H1744-50.

12.

Dostal DE , Baker KM Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart: mediation by the AT1 receptor. Am J Hypertens 1992;5:276-80.

13.

Kim S. , Ohta K. , Hamaguchi A. et al. Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1994;24:195-204.

14.

Zou LX , Imig HK , Von Thun AM , Hymel A. , Ono H. , Navar LG Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II-infused rats. Hypertension 1996;28:669-77.

15.

Raasch W. , Bartels T. , Schwartz C. , Häuser W. , Rütten H. , Dominiak P.

Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors?

J Hypertens 2002;20:2495-504.

16.

Wu R. , Laplante MA , de Champlain J. Prevention of angiotensin II-induced hypertension, cardiovascular hypertrophy and oxidative stress by acetylsalicylic acid in rats. J Hypertens 2004;22:793-801.

17.

Ungvari Z. , Csiszar A. , Kaminski PM , Wolin MS , Koller A. Chronic high pressure-induced arterial oxidative stress. Involvement of protein kinase C-dependent NAD(P)H oxidase and local renin-angiotensin system. Am J Pathol 2004; 165:219-26.

18.

Lee C. , Miura K. , Liu X. , Zweier JL Biphasic regulation of leucocyte superoxide generation by nitric oxide and peroxinitrite. J Biol Chem 2000;275:38965-72.

19.

Ritchie RH , Schiebinger RJ , Lapointe MC , Marsh JD Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Am J Physiol Heart Circ Physiol 1998;275:H1370-4.

20.

De Cavanagh EMV , Inserra F. , Toblli J. , Stella I. , Fraga CG , Ferder L. Enalapril attenuates oxidative stress in diabetic rats. Hypertension 2001;38:1130-6.

21.

Metsarinne KP , Helin KH , Saijonmaa O. , Stewen P. , Sirvio ML , Fyhrquist FY Tissue-specific regulation of angiotensin-converting enzyme by angiotensin II and losartan in the rat. Blood Pressure 1996;5:363-70.

22.

Zhuo JL , Imig JD , Hammond TG , Orengo S. , Benes E. , Navar LG Ang II accumulation in rat renal endosomes during Ang II-induced hypertension. Role of AT1 receptor. Hypertension 2002;39:116-21.

23.

Von Thun AM , Vari RC , El-Dahr SS , Navar LG Augmentation of intrarenal angiotensin II levels by chronic angiotensin II infusion. Am J Physiol (Renal Fluid Electrolyte Physiol 35) 1994;266:F120-28.

24.

Kobori H. , Harrison-Bernard LM , Navar LG Expression of angiotensinogen mRNA and protein in angiotensin IIdependent hypertension. J Am Soc Nephrol 2001;12:431-9.

25.

Harrison-Bernard LM , Zhuo J. , Kobori H. , Ohishi M. , Navar LG Intrarenal AT1 receptor and ACE binding in ANG II-induced hypertensive rats. Am J Physiol Renal Physiol 2002; 281:F19-25.

26.

Campbell DJ , Kladis A. , Duncan AM Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994;23:439-49.

27.

Linz W. , Scholkens BA A specific B2-bradykinin receptor antagonist Hoe140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 19 D 92;105:771-2.

28.

Hutchison FN , Cui X. , Webster SK The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin. J Am Soc Nephrol 1995;6:1216-22.

29.

Pasquie JL , Herizi A. , Jover B. , Mimran A. Chronic bradykinin infusion and receptor blockade in angiotensin II hypertension in rats. Hypertension 1999;33:830-4.